Loading...
In 2014, a multitarget stool DNA test (Cologuard) was approved in the U.S. for colorectal cancer screening, based on a study that established the test's sensitivity and specificity (NEJM JW Gen Med May 1 2014 and N Engl J Med 2014; 370:1287). Now, industry-sponsored researchers present results of a study of a “next generation” stool DNA test, which contains more-recently identified markers of colorectal neoplasia (plus a test for fecal hemoglobin).
About 20,000 asymptomatic adults (mean age, 63) had stool specimens analyzed by the next-generation test and by a commercial fecal immunochemical (FIT) test for comparison; all participants then underwent colonoscopy. Colonoscopy identified colorectal cancer in 98 people and advanced precancerous …